well, it is not like TP 26 means it is to be achieved by next QR.
more like if the QR is good enough, it can continue to rise, fay from 18 to 20... closer to target.
that kenanga report was interesting in that the analyst appeared to be more up to date on the latest ASPs and has gotten new guidance for 2022.
the previous reports, little was mentioned becos no one knows then... now, perhaps visibility for 2022 is a little clearer.
this is very impt as 2022 was previously assumed to be when full vaccines will kick in, demand drops, prices fall.
now, as fresh info and data come out, that may not be quite the case - demand and ASPs may stay elevated for longer...?
we will know more at other coming QRs, reviews and AGMs come on.
Vaccines won't cause ASPs to drop, it's the number of cases that have to be treated, they drop then ASP will drop.
Even when giving vaccines, medical staff still need to take precautions.